Colorectal cancer metastatic+1
RecruitingStudy of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer
Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer
- Disease:Colorectal cancer metastaticColorectal cancer
- Substances:BevacizumabMelphalan+3
Czechia- Participants:18–64 years · 65+ years
- Substances:Bevacizumab














